title: 3' untranslated region 1630 C>T polymorphism of prohibitin increases risk of breast cancer.
abstract: BACKGROUND
  Prohibitin 3' untranslated region 1630 C>T (rs6917) polymorphism creates a variant T allele that lacks the antiproliferative activity of the more common functional C allele. Previous studies indicate that women carrying the prohibitin T allele have an increased susceptibility to breast cancer. However, the role of 1630 C>T polymorphism in mRNA expression of prohibitin and its contribution to carcinogenesis in the breast remains controversial.
  
  
  METHODS
  Using mRNA expression data from the HapMap online database, we sought an association between prohibitin 1630 C>T polymorphism and its mRNA expression, then conducted a meta-analysis of prohibitin 1630 C>T polymorphism and risk of breast cancer.
  
  
  RESULTS
  Although no significant association was found between prohibitin 1630 C>T polymorphism and mRNA expression in lymphoblastoid cell lines from the HapMap database (P trend = 0.543), the present meta-analysis involving 5072 cases and 4796 controls demonstrated that prohibitin 1630 C>T polymorphism was significantly correlated with breast cancer risk in allele contrast model T versus C (odds ratio [OR] 1.09, 95% confidence interval [CI] 1.01-1.18), the homozygote codominant model TT versus CC (OR 1.47, 95% CI 1.12-1.92), and the recessive model TT versus CC/CT (OR 1.45, 95% CI 1.10-1.89).
  
  
  CONCLUSIONS
  Our study indicates that minor allele T of prohibitin 1630 C>T polymorphism is associated with increased susceptibility to breast cancer.
authors: Department of Medical Oncology, Jinling Hospital, Nanjing University School of Medicine, Nanjing, People's Republic of China.
authors: Lin
authors: L
authors: Tang
authors: Yunzhao
authors: Y
authors: Zhao
authors: Weiwei
authors: W
authors: Nie
authors: Zexing
authors: Z
authors: Wang
authors: Xiaoxiang
authors: X
authors: Guan
keywords: breast cancer; genetic; polymorphisms; prohibitin; risk
references: J Mol Histol. 2004 Aug;35(6):639-46
references: 15614618
references: Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1273-4
references: 14652295
references: Lancet. 2002 Sep 21;360(9337):925-6
references: 12354477
references: Oncogene. 1999 Jun 10;18(23):3501-10
references: 10376528
references: Br J Cancer. 2012 Jun 5;106(12):2016-24
references: 22669161
references: Cancer Res. 2003 Sep 1;63(17):5251-6
references: 14500355
references: BMJ. 1997 Sep 13;315(7109):629-34
references: 9310563
references: DNA Cell Biol. 2008 Aug;27(8):449-52
references: 18494604
references: Cell Growth Differ. 1996 Jul;7(7):871-8
references: 8809404
references: BMC Bioinformatics. 2010 Dec 17;11:600
references: 21167019
references: BMJ. 2003 Sep 6;327(7414):557-60
references: 12958120
references: Science. 2007 Feb 9;315(5813):848-53
references: 17289997
references: J Biol Chem. 2003 Nov 28;278(48):47853-61
references: 14500729
references: Lancet. 2001 May 19;357(9268):1588-9
references: 11377649
references: Breast Cancer Res Treat. 2007 Jul;104(1):67-74
references: 17004108
references: Nature. 2003 Dec 18;426(6968):789-96
references: 14685227
references: Exp Cell Res. 1996 Apr 10;224(1):128-35
references: 8612677